Molecular Imaging in Breast Cancer – Potential Future Aspects

Molecular imaging aims to visualize and quantify biological, physiological, and pathological processes at cellular and molecular levels. Recently, molecular imaging has been introduced into breast cancer imaging. In this review, we will present a survey of the molecular imaging techniques that are either clinically available or are being introduced into clinical imaging. We will discuss nuclear imaging and multiparametric magnetic resonance imaging as well as the combined application of molecular imaging in the assessment of breast lesions. In addition, we will briefly discuss other evolving molecular imaging techniques, such as phosphorus magnetic resonance spectroscopic imaging and sodium imaging.

[1]  Molecular imaging of breast lesions with PET-MRI: proof of concept , 2011 .

[2]  A. Rehemtulla,et al.  Molecular Imaging , 2009, Methods in Molecular Biology.

[3]  R. Brem,et al.  Detection of occult foci of breast cancer using breast-specific gamma imaging in women with one mammographic or clinically suspicious breast lesion. , 2010, Academic radiology.

[4]  M. Reza,et al.  A systematic review of FDG-PET in breast cancer , 2010, Medical oncology.

[5]  Elizabeth A Morris,et al.  Diagnostic breast MR imaging: current status and future directions. , 2010, Magnetic resonance imaging clinics of North America.

[6]  Wolfgang Bogner,et al.  A Combined High Temporal and High Spatial Resolution 3 Tesla MR Imaging Protocol for the Assessment of Breast Lesions: Initial Results , 2009, Investigative radiology.

[7]  Wilma van der Riet,et al.  Diffusion-weighted MR imaging with background body signal suppression (DWIBS) for the diagnosis of malignant and benign breast lesions , 2009, European Radiology.

[8]  E. Gasparetto,et al.  Whole-body MRI and FDG PET fused images for evaluation of patients with cancer. , 2009, AJR. American journal of roentgenology.

[9]  D. Fuster,et al.  18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  P. Aspelin,et al.  Diffusion-weighted magnetic resonance imaging of pancreas tumours , 2009, European Radiology.

[11]  B. Pichler,et al.  Pre-clinical PET/MR: technological advances and new perspectives in biomedical research , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  L. Turnbull.  Dynamic contrast‐enhanced MRI in the diagnosis and management of breast cancer , 2009, NMR in biomedicine.

[13]  Gerald Antoch,et al.  Combined PET/MRI: a new dimension in whole-body oncology imaging? , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  John V Frangioni,et al.  New technologies for human cancer imaging. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Rachel F Brem,et al.  Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer. , 2008, Radiology.

[16]  M. Funke,et al.  Bildgebende Diagnostik des Mammakarzinoms , 2008, Der Radiologe.

[17]  M. Tozaki.  Proton MR spectroscopy of the breast , 2008, Breast cancer.

[18]  C. Boetes,et al.  Breast MRI: guidelines from the European Society of Breast Imaging , 2008, European Radiology.

[19]  Kathy Schilling,et al.  The role of positron emission mammography in breast cancer imaging and management , 2008, Applied Radiology.

[20]  A. Fausto,et al.  MR spectroscopy of the breast , 2008, La radiologia medica.

[21]  C. Boetes,et al.  Contrast-enhanced magnetic resonance imaging of the breast: the value of pharmacokinetic parameters derived from fast dynamic imaging during initial enhancement in classifying lesions , 2008, European Radiology.

[22]  K. Togashi,et al.  The utility of diffusion-weighted MR imaging for differentiating uterine sarcomas from benign leiomyomas , 2007, European Radiology.

[23]  T. Helbich,et al.  Magnetic Resonance Imaging of the Breast Improves Detection of Invasive Cancer, Preinvasive Cancer, and Premalignant Lesions during Surveillance of Women at High Risk for Breast Cancer , 2007, Clinical Cancer Research.

[24]  Wei Huang,et al.  Proton (1H) MR spectroscopy of the breast. , 2007, Radiographics : a review publication of the Radiological Society of North America, Inc.

[25]  Carl K Hoh,et al.  Clinical use of FDG PET. , 2007, Nuclear medicine and biology.

[26]  David A Mankoff,et al.  FDG PET, PET/CT, and breast cancer imaging. , 2007, Radiographics : a review publication of the Radiological Society of North America, Inc.

[27]  R. Ouwerkerk.  Sodium magnetic resonance imaging: from research to clinical use. , 2007, Journal of the American College of Radiology : JACR.

[28]  K. Togashi,et al.  Diffusion‐weighted MR imaging of uterine endometrial cancer , 2007, Journal of magnetic resonance imaging : JMRI.

[29]  Hans H Schild,et al.  Effect of B1 inhomogeneity on breast MR imaging at 3.0 T. , 2007, Radiology.

[30]  C. Kuhl.  Current status of breast MR imaging. Part 2. Clinical applications. , 2007, Radiology.

[31]  C. Kuhl.  The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. , 2007, Radiology.

[32]  C. Kuhl.  Breast MR imaging at 3T. , 2007, Magnetic resonance imaging clinics of North America.

[33]  D. Collins,et al.  Diffusion-weighted MRI in the body: applications and challenges in oncology. , 2007, AJR. American journal of roentgenology.

[34]  Gerald Q. Maguire,et al.  Improving Specificity of Breast MRI Using Prone PET and Fused MRI and PET 3D Volume Datasets , 2007, Journal of Nuclear Medicine.

[35]  A. Cilotti,et al.  Quantitative diffusion-weighted MR imaging in the differential diagnosis of breast lesion , 2007, European Radiology.

[36]  Mariko Goto,et al.  Diagnosis of breast tumors by contrast‐enhanced MR imaging: Comparison between the diagnostic performance of dynamic enhancement patterns and morphologic features , 2007, Journal of magnetic resonance imaging : JMRI.

[37]  Thomas E Yankeelov,et al.  Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. , 2007, Magnetic resonance imaging.

[38]  Paul A. Bottomley,et al.  Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive 23Na MRI , 2007, Breast Cancer Research and Treatment.

[39]  Frederik De Keyzer,et al.  Extracranial applications of diffusion-weighted magnetic resonance imaging , 2007, European Radiology.

[40]  D. Winchester.  Pilot Clinical Trial of 18F-Fluorodeoxyglucose Positron-Emission Mammography in the Surgical Management of Breast Cancer , 2006 .

[41]  Min-Ying Su,et al.  Comparison of choline and pharmacokinetic parameters in breast cancer measured by MR spectroscopic imaging and dynamic contrast enhanced MRI. , 2006, Technology in cancer research & treatment.

[42]  Sukru Mehmet Erturk,et al.  High-B-value diffusion-weighted MRI in colorectal cancer. , 2006, AJR. American journal of roentgenology.

[43]  Deepa Narayanan,et al.  High‐Resolution Fluorodeoxyglucose Positron Emission Tomography with Compression (“Positron Emission Mammography”) is Highly Accurate in Depicting Primary Breast Cancer , 2006, The breast journal.

[44]  Wei Huang,et al.  Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. , 2006, Radiology.

[45]  Jürgen Gieseke,et al.  Contrast-enhanced MR imaging of the breast at 3.0 and 1.5 T in the same patients: initial experience. , 2006, Radiology.

[46]  S. Larson,et al.  Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[47]  Ciprian Catana,et al.  Performance test of an LSO-APD detector in a 7-T MRI scanner for simultaneous PET/MRI. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  J. Reichenbach,et al.  Contrast-Enhanced, High-Resolution, Susceptibility-Weighted Magnetic Resonance Imaging of the Brain: Dose-Dependent Optimization At 3 Tesla and 1.5 Tesla In Healthy Volunteers , 2006, Investigative radiology.

[49]  Huanzhou Yu,et al.  Relaxation times of breast tissue at 1.5T and 3T measured using IDEAL , 2006, Journal of magnetic resonance imaging : JMRI.

[50]  R. Hendrick.  Adding in Vivo Quantitative 1H MR Spectroscopy to Improve Diagnostic Accuracy of Breast MR Imaging: Preliminary Results of Observer Performance Study at 4.0 T , 2006 .

[51]  N. Hylton,et al.  Diagnostic architectural and dynamic features at breast MR imaging: multicenter study. , 2006, Radiology.

[52]  Elizabeth A. Morris,et al.  Advances in breast imaging: Magnetic resonance imaging , 2006, Current oncology reports.

[53]  R. Wahl,et al.  Initial experience with FDG-PET/CT in the evaluation of breast cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[54]  A. Ba-Ssalamah,et al.  The value of high-field MRI [3 T] in the assessment of sellar lesions , 2005 .

[55]  Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer. , 2005, American journal of surgery.

[56]  Rachel F Brem,et al.  Occult breast cancer: scintimammography with high-resolution breast-specific gamma camera in women at high risk for breast cancer. , 2005, Radiology.

[57]  Hans H Schild,et al.  Dynamic bilateral contrast-enhanced MR imaging of the breast: trade-off between spatial and temporal resolution. , 2005, Radiology.

[58]  Masahiko Watanabe,et al.  Diffusion-Weighted Imaging of Malignant Breast Tumors: The Usefulness of Apparent Diffusion Coefficient (ADC) Value and ADC Map for the Detection of Malignant Breast Tumors and Evaluation of Cancer Extension , 2005, Journal of computer assisted tomography.

[59]  K. Brandt,et al.  Adding in vivo quantitative 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0 T. , 2005, Radiology.

[60]  Takeo Ishigaki,et al.  Diffusion‐weighted images of the liver: Comparison of tumor detection before and after contrast enhancement with superparamagnetic iron oxide , 2005, Journal of magnetic resonance imaging : JMRI.

[61]  A. Ba-Ssalamah,et al.  The value of high-field MRI (3T) in the assessment of sellar lesions. , 2005, European journal of radiology.

[62]  M. O’Connor,et al.  Molecular breast imaging: a new technique using technetium Tc 99m scintimammography to detect small tumors of the breast. , 2005, Mayo Clinic proceedings.

[63]  R. Taillefer.  Clinical applications of 99mTc-sestamibi scintimammography. , 2005, Seminars in nuclear medicine.

[64]  Takeo Ishigaki,et al.  Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate , 2005, Journal of magnetic resonance imaging : JMRI.

[65]  Mary Scott Soo,et al.  Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. , 2005, Radiology.

[66]  H. Biersack,et al.  Scintimammography with technetium-99m methoxyisobutylisonitrile: comparison with mammography and magnetic resonance imaging , 1996, European Journal of Nuclear Medicine.

[67]  linical Applications of 9 mTc-Sestamibi Scintimammography , 2005 .

[68]  Masanori Ozaki,et al.  ADC mapping of benign and malignant breast tumors. , 2005, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.

[69]  Thomas Beyer,et al.  Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  D. Yee,et al.  Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T. , 2004, Radiology.

[71]  T. Brown,et al.  Methodological standardization for a multi‐institutional in vivo trial of localized 31P MR spectroscopy in human cancer research. In vitro and normal volunteer studies , 2004, NMR in biomedicine.

[72]  Ellen Warner,et al.  Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination , 2004, JAMA.

[73]  D. Schuster,et al.  Molecular imaging in breast cancer. , 2004, Radiologic clinics of North America.

[74]  Neal Rosen,et al.  Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors , 2004, Nature Biotechnology.

[75]  Claudio Landoni,et al.  PET/CT and breast cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[76]  T. Brown,et al.  Predicting treatment response in non-Hodgkin's lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine. , 2004, Academic radiology.

[77]  Gina Caravaglia,et al.  Scintimammography with dedicated breast camera detects and localizes occult carcinoma. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[78]  D. Bluemke,et al.  Proton magnetic resonance spectroscopic imaging of human breast cancer: A preliminary study , 2004, Journal of magnetic resonance imaging : JMRI.

[79]  Robert E. Lenkinski,et al.  The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy , 2001, Breast Cancer Research and Treatment.

[80]  S. Gündoğdu,et al.  The Value of Scintimammography in Reduction Mammaplasties: A Preliminary Study , 2003, Aesthetic Plastic Surgery.

[81]  Winnie C W Chu,et al.  Characterization of lesions of the breast with proton MR spectroscopy: comparison of carcinomas, benign lesions, and phyllodes tumors. , 2003, AJR. American journal of roentgenology.

[82]  A. Kuten,et al.  Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[83]  Siegfried Trattnig,et al.  Effect of Contrast Dose and Field Strength in the Magnetic Resonance Detection of Brain Metastases , 2003, Investigative radiology.

[84]  Paul A Bottomley,et al.  Tissue sodium concentration in human brain tumors as measured with 23Na MR imaging. , 2003, Radiology.

[85]  A. Børresen-Dale,et al.  TP53 and breast cancer , 2003, Human mutation.

[86]  Mohan Doss,et al.  Positron Emission Mammography: Initial Clinical Results , 2003, Annals of Surgical Oncology.

[87]  Mathias K. Fehr,et al.  Follow-up of women with breast cancer: comparison between MRI and FDG PET , 2003, European Radiology.

[88]  M. Schmidt,et al.  Eine Kombination niedrig und hochauflösender dynamischer T1-gewichteter Sequenzen zur besseren Beurteilung der Morphologie Kontrastmittel aufnehmender Läsionen in der MRT der weiblichen Brust , 2002 .

[89]  H J Brambs,et al.  Pre-operative staging of invasive breast cancer with MR mammography and/or PET: boon or bunk? , 2002, The British journal of radiology.

[90]  Ning-Yu An,et al.  Differentiation of clinically benign and malignant breast lesions using diffusion‐weighted imaging , 2002, Journal of magnetic resonance imaging : JMRI.

[91]  L. Liberman,et al.  Breast lesions detected on MR imaging: features and positive predictive value. , 2002, AJR. American journal of roentgenology.

[92]  Rachel F Brem,et al.  High-resolution scintimammography: a pilot study. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[93]  L. Esserman,et al.  Magnetic resonance imaging for primary breast cancer management: current role and new applications. , 2002, Endocrine-related cancer.

[94]  Paul J. van Diest,et al.  Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography , 2002 .

[95]  P. V. van Diest,et al.  Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  M. Thelen,et al.  [Combination of low and high resolution T1-weighted sequences for improved evaluation of morphologic criteria in dynamic contrast enhanced MRI of the breast]. , 2002, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[97]  Javier Villanueva-Meyer,et al.  (99m)Tc sestamibi breast imaging for the examination of patients with dense and fatty breasts: multicenter study. , 2002, Radiology.

[98]  P. Chappuis,et al.  Re: Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. , 2001, Journal of the National Cancer Institute.

[99]  A. Brandes,et al.  Accuracy of technetium-99m sestamibi scintimammography and X-ray mammography in premenopausal women with suspected breast cancer , 2001, European Journal of Nuclear Medicine.

[100]  R L Wahl,et al.  Current status of PET in breast cancer imaging, staging, and therapy. , 2001, Seminars in roentgenology.

[101]  D. Yeung,et al.  Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy--initial results. , 2001, Radiology.

[102]  M D Schnall,et al.  A combined architectural and kinetic interpretation model for breast MR images. , 2001, Academic radiology.

[103]  J. Nelson,et al.  Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. , 2001, Cancer research.

[104]  S. Dwivedi,et al.  Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer , 2001, British Journal of Cancer.

[105]  H. Schirrmeister,et al.  Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures , 2001, European Journal of Nuclear Medicine.

[106]  M. Schwaiger,et al.  Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[107]  J O Barentsz,et al.  Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. , 2001, Journal of the National Cancer Institute.

[108]  C J Thompson,et al.  Results of preliminary clinical trials of the positron emission mammography system PEM-I: a dedicated breast imaging system producing glucose metabolic images using FDG. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[109]  E A Sickles,et al.  Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability. , 2000, AJR. American journal of roentgenology.

[110]  Tc‐99m Sestamibi Scintimammography for the Evaluation of Breast Masses in Patients with Radiographically Dense Breasts , 1999, The breast journal.

[111]  F. Podo.  Tumour phospholipid metabolism , 1999, NMR in biomedicine.

[112]  I. Gribbestad,et al.  Characterization of neoplastic and normal human breast tissues with in vivo 1H MR spectroscopy , 1999, Journal of magnetic resonance imaging : JMRI.

[113]  T. Parrish,et al.  Relationship of elevated 23Na magnetic resonance image intensity to infarct size after acute reperfused myocardial infarction. , 1999, Circulation.

[114]  S. Ilgan,et al.  99Tcm-MIBI scintimammography in the evaluation of breast lesions and axillary involvement: a comparison with mammography and histopathological diagnosis. , 1999, Nuclear medicine communications.

[115]  K R Maravilla,et al.  Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. , 1999, Radiology.

[116]  R. Lenkinski,et al.  Human breast lesions: characterization with proton MR spectroscopy. , 1998, Radiology.

[117]  I. Khalkhali,et al.  Scintimammographic analysis of nonpalpable breast lesions previously identified by conventional mammography. , 1998, Journal of the National Cancer Institute.

[118]  Magnetic-resonance imaging for breast cancer , 1998, The Lancet.

[119]  T. M. Kolb,et al.  Occult cancer in women with dense breasts: detection with screening US--diagnostic yield and tumor characteristics. , 1998, Radiology.

[120]  R Freifelder,et al.  Dedicated PET scanners for breast imaging. , 1997, Physics in medicine and biology.

[121]  T. Helbich,et al.  The diagnostic value of planar and SPET scintimammography in different age groups. , 1997, Nuclear medicine communications.

[122]  M Schwaiger,et al.  Breast imaging with fluorine-18-FDG PET: quantitative image analysis. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[123]  G. de Vincentis,et al.  99mTc-MIBI prone scintimammography in patients with high and intermediate risk mammography. , 1997, Anticancer research.

[124]  G De Vincentis,et al.  A three center study on the diagnostic accuracy of 99mTc-MIBI scintimammography. , 1997, Anticancer research.

[125]  S B Reeder,et al.  Fast 23Na magnetic resonance imaging of acute reperfused myocardial infarction. Potential to assess myocardial viability. , 1997, Circulation.

[126]  A Heinig,et al.  Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions. , 1997, European journal of radiology.

[127]  T Leitha,et al.  Differentiation of benign and malignant breast lesions: MR imaging versus Tc-99m sestamibi scintimammography. , 1997, Radiology.

[128]  A. Schauer,et al.  Prognostic value of contrast-enhanced MR mammography in patients with breast cancer , 1997, European Radiology.

[129]  R. Kim,et al.  Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. , 1996, Circulation.

[130]  M. Greco,et al.  Prone scintimammography in patients with non-palpable breast lesions. , 1996, Anticancer research.

[131]  T E Conturo,et al.  Diffusion MRI: Precision, accuracy and flow effects , 1995, NMR in biomedicine.

[132]  P. Viehweg,et al.  Sensitivity of contrast-enhanced MR imaging of the breast. , 1994, Magnetic resonance imaging clinics of North America.

[133]  I. Mena,et al.  Prone scintimammography in patients with suspicion of carcinoma of the breast. , 1994, Journal of the American College of Surgeons.

[134]  M Hoehn-Berlage,et al.  Quantitative diffusion MR imaging of cerebral tumor and edema. , 1994, Acta neurochirurgica. Supplementum.

[135]  M. Kır,et al.  Clinical Experience with Tc‐99m MIBI Imaging in Patients with Malignant Tumors Preliminary Results and Comparison with TI‐201 , 1992, Clinical nuclear medicine.

[136]  I. Gribbestad,et al.  Contrast-enhanced magnetic resonance imaging of the breast. , 1992, Acta oncologica.

[137]  H. Degani,et al.  Phosphate metabolites and steroid hormone receptors of benign and malignant breast tumors. A nuclear magnetic resonance study , 1991, Cancer.

[138]  W. Kaiser,et al.  MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. , 1989, Radiology.

[139]  D. Paulus.  Imaging in breast cancer , 1987, CA: a cancer journal for clinicians.

[140]  I. Nagy,et al.  Correlation of malignancy with the intracellular Na+:K+ ratio in human thyroid tumors. , 1983, Cancer research.

[141]  I. Cameron,et al.  Intracellular concentration of sodium and other elements as related to mitogenesis and oncogenesis in vivo. , 1980, Cancer research.